ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Damage Index"

  • Abstract Number: 1298 • ACR Convergence 2020

    Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort

    Maria Schletzbaum1, Nnenna Ezeh2, Trevor McKown3, Shivani Garg4 and Christie Bartels5, 1University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, 3William S. Middleton Memorial Veterans Hospital, Madison, WI, 4UW Madison, Madison, WI, 5University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: While medical comorbidities increase with age, younger age at onset of Systemic Lupus Erythematosus (SLE) has been associated with greater risk of some types…
  • Abstract Number: 1393 • ACR Convergence 2020

    Systemic Sclerosis: Subclinical Aterosclerosis and Morbimortality

    Miriam Retuerto1, Jose Luis Rosales2, Maria Martin1, Beatriz Joven1 and Patricia E Carreira1, 1Hospital universitario 12 de octubre, Madrid, Spain, 2Hospiten Rambla, Santa Cruz de Tenerife, Spain

    Background/Purpose: Rheumatic diseases are associated with accelerated atherosclerosis, and an increase in cardiovascular morbidity and mortality. This process is mediated by classic cardiovascular risk factors…
  • Abstract Number: 2036 • ACR Convergence 2020

    Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling

    Ariane Barbacki1, Murray Baron2, Mianbo Wang3, Yuqing Zhang4, Mandana Nikpour5 and Ada Man6, 1McGill University Health Center, Montreal, QC, Canada, 2Jewish General Hospital, Montreal, QC, Canada, 3Lady Davis institute for Medical Research, Montreal, QC, Canada, 4Massachusetts General Hospital, Harvard Medical School, Boston, 5The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, 6University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time.…
  • Abstract Number: 0267 • ACR Convergence 2020

    Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?

    Beatriz Tejera Segura1, Irene Altabás González2, Iñigo Rúa-Figueroa3, Natalia Pérez Veiga4, Victor del Campo Pérez5, Alejandro Olivé-Marqués6, Maria Galindo-Izquierdo7, Jaime Calvo-Alén8, Juan Ovalles-Bonilla9, Antonio Fernandez-Nebro10, Raul Menor Almagro11, Eva Tomero Muriel12, N. Del-val-del-amo13, Maria Esther Uriarte14, VM Martínez Taboada15, Jose Luis Andreu Sanchez16, Alina Lucica Boteanu17, Francisco Javier Narváez18, A Morasat19, Carlos Montilla Morales20, JM Senabre Gallego21, Blanca Hernández Cruz22, Mariano Andrés23, Eva Salgado Pérez24, Mercedes Freire-González25, Sergio Ramon Machin Garcia1, Clara Moriano26, Lorena Expósito27, Clara E. Perez-Velasquez28, ML Velloso-Feijoo29, Ana Paula Cacheda30, Nuria Lozano Rivas31, Gema Bonilla32, Marta Arévalo33, Inmaculada Jimenez34, VE Quevedo-Vila35, Francisco Manero-Ruiz36, Paloma García de la Peña37, TR Vázquez-Rodríguez38, J Ibáñez-Ruan39, Tatiana Cobo-Ibañez40 and Jose Maria Pego-Reigosa41, 1Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 2Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, 4Grupo IRIDIS, Universidad de Vigo, Vigo, Pontevedra, 5Hospital Universitario Meixoeiro, Vigo, Vigo, Pontevedra, Spain, 6Hospital Germans Trias i Pujol, Barcelona, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 9Hospital General Universitario Gregorio Marañón, Madrid, Spain, 10University of Malaga, Malaga, Spain, 11Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, 12Hospital Universitario de la Princesa, Madrid, Madrid, Spain, 13Complejo Hospitalario de Navarra, Pamplona, Spain, 14Hospital Universitario Donostia, San Sebastian, Spain, 15Hospital Universitario Marqués de Valdecilla, Santander, Spain, 16Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 17PRINTO, Istituto Giannina Gaslini, Genova, Italy, 18Hospital Bellvitge, BARCELONA, Spain, 19Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, 20Hospital Universitario de Salamanca, Salamanca, Spain, 21Hospital Marina Baixa, Alicante, Spain, 22Universidad de Sevilla, Sevilla, Spain, 23Hospital General Universitario de Alicante, Alicante, Spain, 24Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 25CHU Coruña, Coruña, Spain, 26Complejo Asistencial Universitario de León, León, Spain, 27Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 28Basurto University Hospital, Bilbao, Spain, 29Hospital Universitario de Valme, Sevilla, Spain, 30Hospital son LLátzer, Palma de Mallorca, Spain, 31Hospital Clínico Universitario Virgen de Arrixaca, Murcia, Spain, 32Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, 33Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, 34Hospital Clínico San Ceciio Granada, Granada, Spain, 35Hospital Comarcal de Monforte, Lugo, Spain, 36Hospital Universitario Miguel Servet, Zaragoza, Spain, 37Hospital HM, Madrid, Spain, 38Hospital Universitario Lucus Augusti, Lugo, Spain, 39Hospital Povisa, Vigo, Pontevedra, Spain, 40Hospital Infanta Sofia, Madrid, Spain, 41University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain

    Background/Purpose: To describe the GI manifestations of SLE in the RELESSER (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology) cohort and…
  • Abstract Number: 0271 • ACR Convergence 2020

    External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus

    Alicia Malone1, Alexandra Legge1 and John Hanly1, 1Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…
  • Abstract Number: 0853 • ACR Convergence 2020

    Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna Gladman2, Jiandong Su3 and Murray Urowitz1, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) patients are usually treated with glucocorticoids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid…
  • Abstract Number: 0864 • ACR Convergence 2020

    Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus

    Lisa Zhu1, Manpreet Singh2, Caroline Siegel3, Lori Sahakian2, Jennifer Grossman4 and Maureen McMahon5, 1University of California, Los Angeles, Van Nuys, CA, 2University of California, Los Angeles, Los Angeles, CA, 3Hospital for Special Surgery, New York, NY, 4University of California, Los Angeles, Sherman Oaks, CA, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated a wide array of beneficial effects in patients with systemic lupus erythematosus (SLE), with regard to disease activity, flare rates,…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology